393 related articles for article (PubMed ID: 26206144)
1. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
[TBL] [Abstract][Full Text] [Related]
2. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
3. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
[TBL] [Abstract][Full Text] [Related]
4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
5. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
6. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
Moss SM; Cuckle H; Evans A; Johns L; Waller M; Bobrow L;
Lancet; 2006 Dec; 368(9552):2053-60. PubMed ID: 17161727
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.
Lång K; Josefsson V; Larsson AM; Larsson S; Högberg C; Sartor H; Hofvind S; Andersson I; Rosso A
Lancet Oncol; 2023 Aug; 24(8):936-944. PubMed ID: 37541274
[TBL] [Abstract][Full Text] [Related]
9. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
10. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
[TBL] [Abstract][Full Text] [Related]
11. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
12. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.
Miller AB; Wall C; Baines CJ; Sun P; To T; Narod SA
BMJ; 2014 Feb; 348():g366. PubMed ID: 24519768
[TBL] [Abstract][Full Text] [Related]
13. Screening for breast cancer with mammography.
Gøtzsche PC; Jørgensen KJ
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD001877. PubMed ID: 23737396
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of mammography screening: updated overview of the Swedish randomised trials.
Nyström L; Andersson I; Bjurstam N; Frisell J; Nordenskjöld B; Rutqvist LE
Lancet; 2002 Mar; 359(9310):909-19. PubMed ID: 11918907
[TBL] [Abstract][Full Text] [Related]
15. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
FH01 collaborative teams
Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
[TBL] [Abstract][Full Text] [Related]
16. The Gothenburg Breast Screening Trial.
Bjurstam N; Björneld L; Warwick J; Sala E; Duffy SW; Nyström L; Walker N; Cahlin E; Eriksson O; Hafström LO; Lingaas H; Mattsson J; Persson S; Rudenstam CM; Salander H; Säve-Söderbergh J; Wahlin T
Cancer; 2003 May; 97(10):2387-96. PubMed ID: 12733136
[TBL] [Abstract][Full Text] [Related]
17. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
18. Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
Allgood PC; Maroni R; Hudson S; Offman J; Turnbull AE; Peacock L; Steel J; Kirby G; Ingram CE; Somers J; Fuller C; Threlfall AG; Gabe R; Maxwell AJ; Patnick J; Duffy SW
Lancet Oncol; 2017 Jul; 18(7):972-980. PubMed ID: 28522311
[TBL] [Abstract][Full Text] [Related]
19. Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.
van den Broek JJ; van Ravesteyn NT; Mandelblatt JS; Huang H; Ergun MA; Burnside ES; Xu C; Li Y; Alagoz O; Lee SJ; Stout NK; Song J; Trentham-Dietz A; Plevritis SK; Moss SM; de Koning HJ
Med Decis Making; 2018 Apr; 38(1_suppl):140S-150S. PubMed ID: 29554468
[TBL] [Abstract][Full Text] [Related]
20. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial.
Heindel W; Weigel S; Gerß J; Hense HW; Sommer A; Krischke M; Kerschke L;
Lancet Oncol; 2022 May; 23(5):601-611. PubMed ID: 35427470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]